Bøker i Cancer Treatment and Research-serien

This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells.The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.

This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention - these fines are playing an important role in changing the landscape for pharmaceutical safety.

This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.

Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited.

This book comprehensively summarizes the current state of knowledge on malignancies of the gastrointestinal tract.

This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites.

This book concisely reviews important advances in radiation oncology, providing practicing radiation oncologists with a fundamental understanding of each topic and an appreciation of its significance for the future of radiation oncology.

This pertinently illustrated and well referenced text serves as an up-to-date, attractive book of oncologic imaging for radiologists, oncologists, radiation therapists and others involved in oncologic care.

Clinical trials remain the most important vehicle for improving the care of cancer patients. Wells, Jr., MD, Professor of Surgery, Duke University Medical Center, Durham, NC, former Director of the American College of Surgeons and Founder of the American College of Surgeons Oncology Group.

This book identifies key treatment challenges and unique care considerations in patients with head and neck cancers, providing a comprehensive guide to patient management that illustrates the critical importance of a multidisciplinary approach in achieving optimal oncological, functional, and survival outcomes.

Peter Angelos Numerous ethical issues arise in the care of oncology patients. Although much has been written in the last several decades on ethical issues in caring for patients, few volumes have sought to focus the exploration on ethical issues particularly relevant to the care of cancer patients.

This book presents expert opinions on a variety of key topics related to the management of breast cancer, with a focus on the implications of recent advances and research findings for clinical practice.

One of the most important aspects of AIDS is the loss of protective immune function in the infected host which leads to increased prevalence of opportunistic infections and cancers. This book specifically addresses viral-induced human cancers associated with AIDS and observed in the AIDS population.

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice.

In the past, pregnancy after cancer was largely unheard of. Oncofertility has emerged as an interdisciplinary field bridging biomedical and social sciences, and examining issues regarding an individual's fertility options, choice and goals in light of cancer diagnosis, treatment and survivorship.

Applying the concept of SSL to the majority of human cancers, this title features a revolutionary concept that might significantly transform surgical cancer treatment. It focuses on cancer metastasis and explores the biological frontier of micro metastasis.

This book presents expert opinions on a variety of key topics related to the management of breast cancer, with a focus on the implications of recent advances and research findings for clinical practice.

This book identifies key treatment challenges and unique care considerations in patients with head and neck cancers, providing a comprehensive guide to patient management that illustrates the critical importance of a multidisciplinary approach in achieving optimal oncological, functional, and survival outcomes.

This book concisely reviews important advances in radiation oncology, providing practicing radiation oncologists with a fundamental understanding of each topic and an appreciation of its significance for the future of radiation oncology.

Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety.

Cancer Informatics in Post-Genomic Era provides both the necessary methodology and practical information tools for analyzing data in the field of medical information science.

Late Effects of Treatment for Brain Tumors reviews the development of the medical team's awareness of late effects of brain tumor treatment and an overview of brain tumor survivorship. It reviews the late effects by topic and by organ systems, educates, and provides guidelines for follow up and interventions for patient survivorship.

The other perspec tive driving the neoadjuvant approach is an emerging awareness that for most solid tumor systems, neoadjuvant treatment responses can facilitate less muti lating surgery with comparable levels of local disease control.

In the past, pregnancy after cancer was largely unheard of. Oncofertility has emerged as an interdisciplinary field bridging biomedical and social sciences, and examining issues regarding an individual's fertility options, choice and goals in light of cancer diagnosis, treatment and survivorship.

While advances in both the treatment of cancer and the management of its complications have led to significant improvement in patient survival, infections remain a significant cause of morbidity and mortality in patients with neo plastic disease.

Cancer Informatics in Post-Genomic Era provides both the necessary methodology and practical information tools for analyzing data in the field of medical information science.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of basic knowledge about the malignant process and about the potential for controlling these malignant diseases. This title covers such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, and hematopoietic stem cells.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.